Innate Pharma SA (OTCMKTS:IPHYF) Short Interest Down 99.8% in May

Innate Pharma SA (OTCMKTS:IPHYF) was the recipient of a significant decrease in short interest during the month of May. As of May 29th, there was short interest totaling 50 shares, a decrease of 99.8% from the May 14th total of 23,016 shares. Based on an average trading volume of 1,489 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the shares of the stock are sold short.

Innate Pharma Stock Performance

Shares of OTCMKTS:IPHYF remained flat at $1.65 during midday trading on Tuesday. The firm’s 50 day moving average is $1.64 and its 200 day moving average is $1.92. Innate Pharma has a twelve month low of $1.37 and a twelve month high of $2.25.

About Innate Pharma

Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.

The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.